As of 3rd of March 2021, there are twelve actively recruiting sites across the UK, Sweden, and Finland.

A total of 533 patients have been recruited onto the study, and recruitment rates continue to increase.

The NOVEL study has continued to be active throughout the COVID-19 pandemic, with all sites operating in a COVID-safe environment, and recruitment predicted to end by the end of 2021.